The Company is focused on bringing well known compounds through the FDA New Drug Application process. Their products have an existing, definable market and are commonly used in hospitals across the country. Currently existing as a 503b compound, the product currently has a USD 20-25 million annual market. The Company is currently profitable with revenues over USD 600,000 per year, which equates to roughly $3.5 million in sales for existing clients through complimentary product sets in secondary wholesale and 503B compounding. Existing revenues support monthly operations while the Company brings its first identified product to market.